

**REVIEW ARTICLE****Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism****Darius Ebrahimi-Fakhari,<sup>1,2</sup> Afshin Saffari,<sup>2</sup> Lara Wahlster,<sup>2,3</sup> Jenny Lu,<sup>1</sup> Susan Byrne,<sup>4</sup> Georg F. Hoffmann,<sup>2,\*</sup> Heinz Jungbluth<sup>4,5,6,\*</sup> and Mustafa Sahin<sup>1,\*</sup>**

\*These authors contributed equally to this work.

Single gene disorders of the autophagy pathway are an emerging, novel and diverse group of multisystem diseases in children. Clinically, these disorders prominently affect the central nervous system at various stages of development, leading to brain malformations, developmental delay, intellectual disability, epilepsy, movement disorders, and neurodegeneration, among others. Frequent early and severe involvement of the central nervous system puts the paediatric neurologist, neurogeneticist, and neuro-metabolic specialist at the forefront of recognizing and treating these rare conditions. On a molecular level, mutations in key autophagy genes map to different stages of this highly conserved pathway and thus lead to impairment in isolation membrane (or phagophore) and autophagosome formation, maturation, or autophagosome-lysosome fusion. Here we discuss ‘congenital disorders of autophagy’ as an emerging subclass of inborn errors of metabolism by using the examples of six recently identified monogenic diseases: *EPG5*-related Vici syndrome, beta-propeller protein-associated neurodegeneration due to mutations in *WDR45*, *SNX14*-associated autosomal-recessive cerebellar ataxia and intellectual disability syndrome, and three forms of hereditary spastic paraplegia, *SPG11*, *SPG15* and *SPG49* caused by *SPG11*, *ZFYVE26* and *TECPR2* mutations, respectively. We also highlight associations between defective autophagy and other inborn errors of metabolism such as lysosomal storage diseases and neurodevelopmental diseases associated with the mTOR pathway, which may be included in the wider spectrum of autophagy-related diseases from a pathobiological point of view. By exploring these emerging themes in disease pathogenesis and underlying pathophysiological mechanisms, we discuss how congenital disorders of autophagy inform our understanding of the importance of this fascinating cellular pathway for central nervous system biology and disease. Finally, we review the concept of modulating autophagy as a therapeutic target and argue that congenital disorders of autophagy provide a unique genetic perspective on the possibilities and challenges of pathway-specific drug development.

- 1 The F.M. Kirby Neurobiology Centre, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
- 2 Division of Paediatric Neurology and Inherited Metabolic Diseases, Department of Paediatrics, Heidelberg University Hospital, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany
- 3 Department of Haematology and Oncology, Stem Cell Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
- 4 Department of Paediatric Neurology, Evelina’s Children Hospital, Guy’s and St. Thomas’ Hospital NHS Foundation Trust, London, UK
- 5 Randall Division for Cell and Molecular Biophysics, Muscle Signalling Section, King’s College London, London, UK
- 6 Department of Basic and Clinical Neuroscience, IoPPN, King’s College London, London, UK

Correspondence to: Dr Darius Ebrahimi-Fakhari,  
The F.M. Kirby Neurobiology Centre,

Department of Neurology, Boston Children's Hospital,  
Harvard Medical School,  
3 Blackfan Circle, CLSB 14060, MA 02115,  
USA  
E-mail: darius.ebrahimi-fakhari@childrens.harvard.edu

**Keywords:** autophagy; inborn errors of metabolism; mammalian target of rapamycin (mTOR); neurodevelopment; neurodegeneration

**Abbreviations:** AMPK = AMP-activated protein kinase; Atg = autophagy-related gene/protein; BPAN = beta-propeller protein-associated neurodegeneration; HSP = hereditary spastic paraplegia; iPSC = induced pluripotent stem cell; mTOR = mammalian target of rapamycin; mTORC1 = mammalian target of rapamycin complex 1

## Introduction

Inborn errors of metabolism comprise a large group of single gene disorders that affect various aspects of cellular metabolism. Based on the specific pathway involved, such conditions can be categorized as disorders of carbohydrate metabolism, amino or organic acid metabolism, fatty acid oxidation and mitochondrial metabolism, lysosomal diseases, peroxisomal disorders, and others. While these conditions are traditionally considered 'enzymopathies' due to the interruption of specific pathways with resulting accumulation of toxic or interfering intermediate products and/or reduced ability to synthesize an essential metabolite, the recent introduction of next-generation sequencing into diagnostics has resulted in the identification and characterization of novel inborn errors of metabolism.

One such cellular pathway for inborn errors of metabolism that has emerged in recent years is the autophagy pathway, with a number of genetic defects leading to inherited multisystem diseases with prominent nervous system involvement. The prominent involvement of the CNS, peripheral nerves and skeletal muscles, often in the same patient, puts neurologists and neurogeneticists at the forefront for diagnosing and treating 'congenital disorders of autophagy'. Putative single gene disorders of the autophagy pathway provide a 'genetic window' into the role of autophagy in humans and will inform our understanding of this fascinating pathway and its implications for neurobiology and disease. The latter is particularly important, given that dysregulated autophagy has been implicated in many other inherited and sporadic diseases, including neurodegenerative and neurodevelopmental diseases (Pan *et al.*, 2008a; Ebrahimi-Fakhari *et al.*, 2012, 2014; Nixon, 2013; Ebrahimi-Fakhari and Sahin, 2015), myopathies (Ravenscroft *et al.*, 2015), cardiovascular diseases (Lavandro *et al.*, 2013), cancer (Galluzzi *et al.*, 2015), infectious diseases (Huang and Brumell, 2014), and metabolic diseases (Christian *et al.*, 2013), all of which also affect the CNS.

We herein discuss 'congenital disorders of autophagy' as an emerging subclass of inborn errors of metabolism by using the examples of six monogenic diseases of autophagy that affect the brain (Table 1). We also highlight associations between defective autophagy and other inborn errors

of metabolism such as lysosomal storage diseases and neurodevelopmental diseases, such as those associated with the mTOR pathway.


## The autophagy pathway

Autophagy (Greek for 'self-eating') is the umbrella term for essential intracellular pathways that deliver cytosolic cargo to lysosomes for degradation (reviewed in Ravikumar *et al.*, 2010; Klionsky *et al.*, 2011; Kaushik and Cuervo, 2012; Feng *et al.*, 2014) (see Supplementary Table 1 for a glossary of autophagy-related molecules and processes). At least three subtypes of autophagy have been characterized according to the mechanism of cargo delivery: microautophagy, chaperone-mediated autophagy, and macroautophagy (Fig. 1). Microautophagy uses inward invagination of the lysosomal membrane to deliver cytoplasmic cargo directly to the lysosome for degradation. Chaperone-mediated autophagy selectively recognizes targeting motifs (KFERQ-like motifs) on cytosolic proteins and translocates targeted proteins across the lysosomal membrane with the help of chaperone-proteins and the lysosomal adapter protein LAMP-2A. Macroautophagy uses the *de novo* formation of double-membrane vesicles to sequester parts of the cytosol containing proteins, lipids, and organelles. The basic principles underlying autophagy are highly conserved from yeast to mammals, highlighting the fundamental importance of this pathway for cellular homeostasis and survival. Beyond the turnover of macromolecules and organelles, recent studies have implicated a role for autophagy in related cell functions such as membrane trafficking, regulation of energy metabolism (Efeyan *et al.*, 2015), adaptive immunity (Gomes and Dikic, 2014), and cell death (Green and Levine, 2014).

In this review, we focus on macroautophagy (hereafter referred to as autophagy), the 'bulk' degradation process that is characterized by the formation of double-membrane bound autophagic vesicles, which undergo a dynamic stepwise maturation process: initiation, nucleation of an isolation membrane, elongation of evolving vesicles, closure, maturation, and finally fusion with late endosomes or lysosomes (Figs 1 and 2). The unique double-membrane autophagic vesicle is named the autophagosome, while the fusion

**Table 1** Congenital disorders of autophagy

Disease (# OMIM)	Gene	Affected stage of the autophagy pathway	Neurological manifestations
Vici syndrome (#242840)	EPG5	Late stages: Autophagosome-lysosome fusion Proteolysis within autolysosomes	Agenesis of the corpus callosum and other congenital brain malformations Delayed myelination and white matter atrophy Acquired microcephaly and dysmorphic features Developmental delay/developmental regression Failure to thrive Muscular hypotonia Seizures
Beta-proPELLER protein-associated neurodegeneration (#300894)	WDR45	Early stages: Autophagosome elongation	Sensorineural deafness Childhood: Developmental delay / intellectual disability Seizures Spastic paraplegia Rett-like stereotypies Autistic features Adolescence: Progressive dementia Parkinsonism, dystonia Optic nerve atrophy Sensorineural hearing loss Bladder and bowel incontinence Sleep disorder Progressive cerebellar atrophy and ataxia Developmental delay / intellectual disability Muscular hypotonia Seizures
SNX14-associated autosomal-recessive cerebellar ataxia and intellectual disability syndrome (#616105)	SNX14	Late stage: Autophagosome-lysosome fusion (probably)	Autistic features Storage disease phenotype Progressive spasticity and weakness of the lower limbs Developmental delay/cognitive decline Thinning of the corpus callosum Axonal, motor, or sensorimotor peripheral neuropathy Pseudobulbar involvement with dysarthria and dysphagia Less common: Retinal degeneration (Kjellin syndrome) Cerebellar ataxia Parkinsonism
Hereditary spastic paraplegia: SPG11 (#604360) and	SPG11 and ZFYVE26	SPG11: Late stage: Lysosome reformation/biogenesis SPG15: Early, middle and late stages: Autophagosome initiation / nucleation Autophagosome maturation Autophagosome-lysosome fusion Lysosome reformation / biogenesis Early stages: Autophagosome nucleation (probably)	Progressive spasticity and weakness of the lower limbs Developmental delay/cognitive decline Muscular hypotonia Microcephaly and dysmorphic features Cerebellar dysfunction Central apnoea Seizures Thinning of the corpus callosum
Hereditary spastic paraplegia: SPG49 (#615031)	TECPR2		




**Figure 1** The three main subtypes of autophagy and their implications for multiple tissues and organ systems. Autophagy mainly comprises of three subtypes: microautophagy, chaperone-mediated autophagy and macroautophagy. These are distinguished based on the route and mechanism of cargo delivery to lysosomes, the final degrading organelles. Research over the last decades has elucidated a number of cell and tissue-specific functions that depend on or are critically influenced by autophagy. These functions are present in many organ systems, including the nervous system. The variety of functions of autophagy in different organ systems under physiological conditions is emphasized by the broad clinical manifestations in congenital disorders of autophagy, which manifest as multisystem diseases with prominent CNS pathology. CMA = chaperone-mediated autophagy.

product of autophagosomes and lysosomes is referred to as the autolysosome. Although autophagy has been generally thought of as a non-specific degradation pathway, several specific forms of autophagy have been identified in recent years. Examples of specific forms of autophagy include the selective removal of damaged mitochondria (or ‘mitophagy’; Ashrafi and Schwarz, 2013), peroxisomes (or ‘pexophagy’; Oku and Sakai, 2010), ribosomes (or ‘ribophagy’; Suzuki, 2013), aberrant protein aggregates (or ‘aggrephagy’; Yamamoto and Simonsen, 2011), and lipid droplets (or ‘lipophagy’; Liu and Czaja, 2013). Post-translational modifications such as ubiquitination or phosphorylation are critical for recruiting and tailoring the autophagy machinery to each specific cargo (Okamoto, 2014) and thus might serve as a target for developing therapeutic approaches. Ubiquitination seems to be particularly important to label cargo for autophagy, and a number of autophagy receptors with an ubiquitin-binding domain (such as p62/SQSTM1, NBR1, NDP52 or optineurin) have been

identified, adding a level of plasticity and precision to the autophagy machinery (Stolz *et al.*, 2014). p62/SQSTM1 is of particular interest because it is not only an important adapter protein for ubiquitinated cargo (Wurzer *et al.*, 2015), but also a substrate for autophagic degradation (Bjorkoy *et al.*, 2005; Komatsu *et al.*, 2007a). Cells deficient in autophagy therefore often accumulate protein aggregates that contain p62, making this a widely used assay to detect autophagy deficits (Klionsky *et al.*, 2012).

Autophagy is constitutively active to some extent in all cells at any given time in order to maintain a homeostatic balance between catabolic and anabolic processes. To dynamically adjust autophagic activity to the intracellular metabolic state and the extracellular environment, numerous signalling pathways converge to regulate autophagy initiation (Fig. 2), many of these via mTORC1 (mammalian target of rapamycin complex 1; Lipton and Sahin, 2014) or AMPK (AMP-activated protein kinase; Alers *et al.*, 2012). Maintenance of baseline autophagic flux is essential to





**Figure 2 Macroautophagy: an overview of the molecular pathway and mutations associated with congenital disorders of autophagy.** Macroautophagy is a step-wise process resulting in the formation of double-membrane-bound autophagic vesicles that engulf their cargo before fusing with lysosomes. The principle stages of macroautophagy include: (I) initiation; (II) nucleation of an isolation membrane (also called phagophore); (III) elongation of evolving autophagic vesicles; (IV) engulfment of cargo and closure of the autophagosomal membrane; (V) autophagosome maturation; (VI) fusion with late endosomes or lysosomes; and finally (VII) degradation of cargo through lysosomal hydrolases. The last step yields basic metabolites that are then recycled. Mutations in congenital disorders of autophagy and single gene disorders associated with deficits in the regulation of autophagy impair different stages of the pathway. Through interfering with the beclin I complex, hereditary spastic paraplegia-associated recessive mutations in *ZFYVE26* (*SPG15*) impair early stages such as the formation of the isolation membrane. Mutations in *TECPR2* (*SPG49*) were recently shown to be critically involved in maintaining endoplasmic reticulum exit sites that may serve as scaffolds for the formation of early autophagosome intermediates. X-linked *WDR45* mutations cause beta-propeller protein-associated neurodegeneration (*BPAN*) and have been found to potentially interfere with the elongation of nascent autophagic vesicles. Autosomal-recessive *EPG5* mutations in Vici syndrome as well as *SNX14* mutations in *SNX14*-associated autosomal-recessive cerebellar ataxia and intellectual disability syndrome impact the late stages of the autophagy pathway through impairing autophagosome-lysosome fusion. Mutations in *SPG11* (*SPG11*) lead to a defect in autophagic lysosome reformation. Autophagy-associated diseases also affect different stages of autophagy regulation. An example for mTOR-associated neurodevelopmental diseases, loss-of-function mutations in *TSC1* or *TSC2* in tuberous sclerosis complex lead to constitutive activation of mTORC1 and thus block autophagic flux at multiple stages. Locating the defect to the late stages of the pathway, lysosomal storage diseases impact lysosomal metabolism and thus block upstream steps in the autophagy pathway. Impaired crosstalk between the lysosomal pathway and autophagosome biogenesis might also impact the coordinated regulation of both compartments. AR-CAID = autosomal-recessive cerebellar ataxia and intellectual disability syndrome; LSD = lysosomal storage disease; TSC = tuberous sclerosis complex.

neurons, skeletal and cardiac muscle. This probably explains the increased vulnerability of these tissues to deficits in autophagy and may account for the prominent neurological and neuromuscular manifestations in primary disorders of autophagy. Specific differences in autophagy regulation and baseline autophagic flux in highly differentiated, post-mitotic cells such as neurons remain to be explored in detail, and might help to explain the preferential degeneration of specific neuronal subtypes such as cerebellar Purkinje cells or long-projecting cortical neurons that form projecting or commissural connections. On a similar note, while the role of autophagy in neuronal physiology is increasingly appreciated, the contribution of defective glial autophagy to neurodegenerative phenotypes in mice (Hara *et al.*, 2006; Komatsu *et al.*, 2006, 2007b; Nishiyama *et al.*, 2007) and humans (see below) with defective autophagy remains relatively unexplored.

Following pioneering work in yeast, many proteins and mechanisms in mammalian autophagy have been uncovered. Multiple autophagy-related proteins (Atg) coordinate the different steps of autophagosome formation and turnover (Fig. 2, see Supplementary Table 1 for a glossary of autophagy-related molecules and processes discussed here). The induction step in the autophagy cascade is critically determined by the phosphorylation status of the ULK1-ATG13-FIP200 complex, which drives the nucleation of the isolation membrane (Wong *et al.*, 2013) (Fig. 2). Under normal nutrient conditions, active mTORC1 phosphorylates ULK1 (unc-51 like autophagy activating kinase 1) and ATG13 to repress ULK1 kinase activity, thereby inhibiting autophagy (Ganley *et al.*, 2009; Hosokawa *et al.*, 2009; Jung *et al.*, 2009; Kim *et al.*, 2011). On the other hand, cell stress induced by starvation, amino acid deprivation, or growth factor withdrawal inhibits mTORC1 activity, leading to autophagy induction (Wong *et al.*, 2013).

AMPK, the second kinase at the heart of autophagy regulation, is a major positive regulator of autophagy under stress conditions. Under conditions of low intracellular energy (when the ration of AMP to ATP is high), activated AMPK induces autophagy both by phosphorylating ULK1 (at a different site than mTORC1) and by inhibiting mTORC1 (Egan *et al.*, 2011; Kim *et al.*, 2011; Di Nardo *et al.*, 2014). Both AMPK and mTOR also control cell growth and metabolism, thereby coupling these processes to autophagy.

In the next step of the autophagic cascade, formation of an isolation membrane is initiated by a second protein complex, the beclin 1-Atg14L-VPS34 kinase complex, which enriches the initiation site with phosphatidylinositol-3-phosphate to recruit interacting regulatory proteins such as Atg9 (Funderburk *et al.*, 2010) (Fig. 2). Atg9 serves as an important adapter molecule that recruits membranes and lipids to expand the isolation membrane (Mari *et al.*, 2010; Orsi *et al.*, 2012; Yamamoto *et al.*, 2012). At a regulatory level, phosphorylation of beclin 1 by Akt inhibits autophagy (Wang *et al.*, 2012b), while phosphorylation at a different residue by AMPK or ULK1 promotes its

integration into the beclin 1-Atg14L-VPS34 kinase complex and initiates autophagy (Kim *et al.*, 2013; Russell *et al.*, 2013). Likewise, phosphorylation of Atg9 by ULK1 is required for the efficient recruitment of additional factors to the formation site and subsequent expansion of the isolation membrane (Papinski *et al.*, 2014).

The precise subcellular location where the isolation membrane is formed remains controversial, with the endoplasmic reticulum, Golgi complex, plasma membrane, recycling endosomes, and mitochondrial membrane being putative candidates (Lamb *et al.*, 2013). It seems likely that membranes are derived from multiple sources and perhaps in a cell type- or even location-specific manner, e.g. it is conceivable that the source of autophagic membranes might be different in distal neurites compared to the cell body. Elongation of evolving autophagosomes requires two ubiquitin-like conjugation systems: the ATG5-ATG12-ATG16L1 and the LC3 (microtubule-associated protein light chain 3 or Atg8; encoded by *MAP1LC3A*)–phosphatidylethanolamine conjugation system (Mizushima *et al.*, 2011) (Fig. 2); the former functions as an E3 ligase that mediates the lipidation of LC3, whereas lipidated LC3 and its family members GATE16 (*GABARAPL2*) and GABARAP are coupled to the autophagosomal membrane where they support its elongation and closure. The lipidated form of LC3, LC3-II, is of particular interest as it localizes to the inner and outer autophagosomal membrane, making this protein a widely used marker to identify and quantify autophagosome formation and turnover (Klionsky *et al.*, 2012).

Fusion with lysosomes, the final step in the life cycle of autophagosomes, often occurs in the perinuclear region, where the bulk of lysosomes usually reside. Autophagic vesicles, however, almost certainly form everywhere in the cell and thus have to be shipped towards the perinuclear region by dynein-dependent retrograde transportation on microtubules. This process is particularly important for neurons with their long processes (Maday *et al.*, 2012; Cheng *et al.*, 2015). Local autophagic degradation, for example of damaged mitochondria (Ashrafi *et al.*, 2014), might be another important contributor to homeostasis in remote cellular regions such as distal axons, where most of the axonal autophagosomes form (Maday and Holzbaur, 2014). Lysosomal enzymes efficiently degrade the sequestered cargo, and the basic building blocks are recycled back to the cytosol for reuse. After cargo degradation, lysosomal components are also retrieved from autolysosomes to replenish the lysosomal pool (Yu *et al.*, 2010).

Not surprisingly, lysosomal metabolism is intimately coupled to autophagy regulation. This is achieved on the transcriptional level through a recently described pathway that involves the master regulator of both lysosomal and autophagic vesicle biogenesis, the basic helix-loop-helix leucine-zipper transcription factor EB (TFEB). TFEB regulates the expression of the coordinated lysosomal expression and regulation (CLEAR) network of genes involved in lysosomal biogenesis and autophagy (Sardiello *et al.*, 2009;

Palmieri *et al.*, 2011; Settembre *et al.*, 2011). Interestingly, mTORC1 associates and phosphorylates TFEB at the lysosomal membrane under conditions of nutrient sufficiency and thus prevents its translocation to the nucleus. In response to cellular energy depletion, however, mTORC1-dependent phosphorylation of TFEB is impaired, triggering the transcription of genes that encode proteins required for autophagosome formation and autophagic flux (Martina *et al.*, 2012; Rocznik-Ferguson *et al.*, 2012). Given its central role in regulating the autophagy-lysosomal pathway, TFEB has gained significant attention as a potential therapeutic target for diseases where defective autophagy and/or lysosomal dysfunction have been implicated, such as hepatic  $\alpha$ 1-antitrypsin deficiency (Pastore *et al.*, 2013), Pompe disease (Spampanato *et al.*, 2013), Parkinson's disease (Decressac *et al.*, 2013) or Huntington's disease (Tsunemi *et al.*, 2012).

## Congenital disorders of autophagy

The emergence of rapid and more widely available next-generation DNA sequencing technology has led to the identification of the genetic basis of many rare diseases, including inborn errors of metabolism. Single gene disorders affecting the autophagy pathway are increasingly identified, and genetic variants in autophagy genes are found to contribute to a number of major diseases. Here we discuss six 'congenital disorders of autophagy' (Table 1) that predominantly affect the brain and argue for a novel subclass of inborn errors of metabolism.

### Vici syndrome: EPG5 mutations


First described by Dionisi-Vici *et al.* (1988), Vici syndrome (OMIM #242840) is a rare autosomal recessive multisystem disease with ~50 published cases to date (Dionisi Vici *et al.*, 1988; del Campo *et al.*, 1999; Chiyonobu *et al.*, 2002; Miyata *et al.*, 2007; Al-Owain *et al.*, 2010; McClelland *et al.*, 2010; Rogers *et al.*, 2011; Finocchi *et al.*, 2012; Ozkale *et al.*, 2012; Said *et al.*, 2012; Cullup *et al.*, 2013, 2014; Ehmke *et al.*, 2014; Filloux *et al.*, 2014; Tasdemir *et al.*, 2015; Byrne *et al.*, in press). Vici syndrome is classically characterized by a set of five cardinal features that include agenesis of the corpus callosum, bilateral cataracts, hypertrophic and/or dilated cardiomyopathy, combined immunodeficiency, and skin, hair and retinal hypopigmentation (Fig. 3). These five manifestations in addition to three features recently identified to occur in the majority of Vici patients, namely acquired microcephaly, failure to thrive and profound developmental delay, allow a clinical diagnosis that is confirmed by a positive genetic test with a specificity and sensitivity of >90% (Byrne *et al.*, in press). Congenital midline defects such as a cleft lip or palate, thymic aplasia or congenital deficiency

of the thymus, and hypospadias may also occur but are less frequent. Additional general findings include facial dysmorphism, dysphagia, recurrent pulmonary and mucocutaneous infections secondary to immunodeficiency, and neonatal-onset hypotonia secondary to myopathy. Chronic anaemia, renal tubular acidosis, liver dysfunction, and lung hypoplasia have also been described in a few cases (Fig. 3).

The neurological phenotype is broad and, in addition to the prominent feature of agenesis of the corpus callosum (often with colpocephaly), which occurs in almost all patients, involves other brain malformations such as non-lissencephalic cortical or cerebellar vermis dysplasia, pontine hypoplasia, abnormalities of the septum pellucidum, abnormal T<sub>2</sub> signal diffusely in the thalami, and myelination defects (Table 1 and Fig. 3). Of these secondary features, reduced white matter bulk and under-opercularization of the Sylvian fissures are found in the majority of patients. Post-mortem examination of a single case confirmed agenesis of the corpus callosum as well as prominent hypoplasia of the pons and cortico-spinal tracts. Neurological sequelae are manifold and include progressive postnatal microcephaly, profound developmental delay and intellectual disability, motor impairment, nystagmus, sensorineuronal deafness, and seizures (Table 1 and Fig. 3). In infancy, the latter frequently evolve into epileptic encephalopathy that is often refractory to treatment. Interestingly, the reported loss of previously acquired skills as well as the occurrence of progressive microcephaly in Vici patients who survive the neonatal period, suggest a neurodegenerative component in addition to the prominent neurodevelopmental defects. This notion is corroborated by a neurodegenerative phenotype in *Epg5*-deficient *Drosophila melanogaster* (CG14299; Byrne *et al.*, in press) and transgenic mice (Zhao *et al.*, 2013a) as discussed below. The disease is usually fatal in infancy or early childhood with recurrent, severe infections and/or progressive heart failure likely being the main cause of mortality.

Using whole-exome sequencing in affected individuals, Cullup *et al.* (2013) identified recessive mutations in the *EPG5* gene on chromosome 18q12.3 as the genetic cause of Vici syndrome. *EPG5* consists of 44 exons encoding a protein of 2579 amino acids at maximum. The mutations identified so far map to almost the entire gene with no clear mutational hotspot. Most mutations are predicted to lead to a truncated protein product, thus favouring a loss-of-function mechanism. *EPG5* is the human homologue of the metazoan-specific autophagy gene *Epg5* (ectopic P-granule autophagy protein 5), which encodes the key regulatory autophagy protein Epg5. Like many autophagy-related genes, *Epg5* first emerged in a *Caenorhabditis elegans*-based genetic screening for modifiers of autophagic substrate degradation. Mutant *epg-5* in *C. elegans*, as well as a gene knockdown in mammalian cells, was found to result in the accumulation of dysfunctional non-degenerative autolysosomes, arguing that *EPG5* is critically involved in the late stages of the autophagy cascade such as autophagosome-





**Figure 3 Vici syndrome: a multisystem disease.** Mutations in the autophagy gene *EPG5* cause Vici syndrome, a paradigm for multisystem diseases associated with defective autophagy. The eight cardinal features of Vici syndrome consist of agenesis of the corpus callosum, acquired microcephaly, bilateral cataracts, hypertrophic or dilated cardiomyopathy, combined immunodeficiency, and skin, hair or retinal hypopigmentation, failure to thrive and profound developmental delay. CNS manifestations are manifold and include congenital brain malformations such as agenesis of the corpus callosum with colpocephaly, cerebellar hypoplasia, hypoplasia/atrophy of the brainstem, abnormalities of the septum pellucidum, opercular hypoplasia and probably age-dependent abnormal T<sub>2</sub> signal in the thalami. Dysgenesis of the falx, non-lissencephalic cortical dysplasia, polymicrogyria of the cerebral hemispheres, or bilateral schizencephaly have also been reported in a few individuals. Delayed myelination and diffuse white matter atrophy are commonly reported. Pointing to the potential presence of a neurodegenerative phenotype in addition to prominent deficits in brain development, dilated ventricles, Purkinje cell loss, and diffuse cerebral atrophy have been described in a subset of patients.

lysosome fusion or proteolysis within autolysosomes (Tian *et al.*, 2010; Zhao *et al.*, 2013a).

Further delineating the role of *EPG5*, characterization of autophagy in skeletal muscle tissue and fibroblasts from Vici patients revealed an accumulation of LC3-positive autophagic vesicles, and of the autophagy linker-proteins NBR1 and p62. This suggests a block in autophagic flux, a finding further corroborated by the accumulation of K63-polyubiquitinated proteins, which are usually targeted for autophagic degradation. Evidence for a block at the late stages of autophagy, namely during autophagosome–lysosome fusion, was provided by showing a reduction in the co-localization of both organelles (Cullup *et al.*, 2013). In retrospect, these findings are consistent with earlier studies in available muscle biopsies from Vici patients that found abundant vacuoles and dense bodies suggesting a lysosomal origin (Al-Owain *et al.*, 2010; McClelland *et al.*, 2010; Cullup *et al.*, 2013).

In summary, *EPG5* deficiency in Vici syndrome leads to a critical impairment of the late stages of the autophagy

pathway (Table 1 and Fig. 2). Global reduction in autophagic flux leads to impaired development and function in a multitude of tissues and thus to a multisystem disease (Fig. 3). Recurrent infections are a significant source of morbidity and mortality in Vici syndrome. This might be secondary to the fact that defective autophagy impairs immunity and the clearance of intracellular pathogens in particular, as this has been recently found to critically depend on intact autophagy (Jo *et al.*, 2013). Despite the convincing role for *EPG5* mutations in human cases, *Epg5* knockout mice do not fully recapitulate the phenotype found in Vici syndrome and interestingly resemble instead key neuropathological features of the neurodegenerative disease amyotrophic lateral sclerosis (Zhao *et al.*, 2013a). Neurodegeneration mainly occurs in cortical pyramidal neurons and motor neurons of the spinal cord and is accompanied by accumulation of p62-positive and ubiquitinated protein aggregates. Not surprisingly, knockout mice display progressive motor deficits and die around 12 months of age. Muscle atrophy, fibrillations




and sharp waves on electromyography indicate active denervation. Interestingly, in addition to the degenerative changes secondary to denervation, glycogen accumulation is found in skeletal muscle of *Epg5* deficient mice arguing for a ‘storage disease phenotype’ similar to glycogen accumulation observed in muscle and other tissues from patients with Vici syndrome (Al-Owain *et al.*, 2010; McClelland *et al.*, 2010; Cullup *et al.*, 2013). Although no overt developmental brain malformations were discovered, *Epg5* deficient mice were consistently found to have a reduced thickness of the corpus callosum with a partial or complete agenesis in a few knockout animals (Zhao *et al.*, 2013b). Thus, while *Epg5* knockout mice show some phenotypic similarities to patients with Vici syndrome, including corpus callosum dysgenesis and myopathy, core clinical features, however, are not recapitulated. Nevertheless, Vici syndrome, a multisystem disease in humans, is an important example for the concept of ‘congenital disorders of autophagy’ as it highlights the consequences of dysfunctional autophagy for organ development and the complex role of autophagy in CNS development.

## Beta-propeller protein-associated neurodegeneration: WDR45 mutations

Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically heterogeneous group of single gene disorders characterized by dysregulation of iron metabolism leading to iron deposits in the basal ganglia, particularly in the globus pallidus and substantia nigra (Horvath, 2013; Meyer *et al.*, 2015). A recently identified subtype within this group is beta-propeller protein-associated neurodegeneration (BPAN), a disease that had been previously summarized under the term ‘static encephalopathy of childhood with neurodegeneration in adulthood’ (SENDA) syndrome, based on its distinct pattern of clinical and MRI findings and its characteristic natural history (Fig. 4). BPAN accounts for ~1–2 % of all NBIA cases and is the only form of the disease with an X-linked dominant inheritance pattern, although thus far only patients carrying *de novo* mutations have been reported (Haack *et al.*, 2012; Saitsu *et al.*, 2013; Nishioka *et al.*, 2015).

Clinically, BPAN is a biphasic disease that begins with global developmental delay in infancy or early childhood (Table 1 and Fig. 4) (Hayflick *et al.*, 2013; Nishioka *et al.*, 2015). Seizures of various types including generalized tonic-clonic but also focal, absence, atonic or myoclonic seizures are frequent initial presentations, often in the context of a febrile illness. Spastic paraparesis is another commonly reported early finding. Symptoms remain relatively static until the second phase of the disease suddenly begins in adolescence or early adulthood with progressive cognitive decline, dementia, dystonia, and parkinsonism dominating the clinical picture. The latter mainly consists of bradykinesia, rigidity and postural instability while tremor is not



**Figure 4 BPAN: natural history of a biphasic disease.**

Patients with *WDR45*-mutation associated BPAN commonly present with a distinct biphasic clinical course. Initial manifestations in infancy or early childhood consist of global developmental delay, intellectual disability, and seizures, which tend to progress in the later stages of the disease. Cerebellar ataxia, spasticity, Rett-like hand stereotypies, and autistic features have also been reported in a subset of patients. The disease advances in adolescence or early adulthood when dystonia, parkinsonism, and progressive cognitive decline become prominent. Other manifestations often include bladder and bowel incontinence, disordered sleep, and visual and auditory deficits.

commonly seen. In a number of cases, these symptoms have responded to levodopa (Hayflick *et al.*, 2013). Seizures, too, usually progress in the adult phase of the disease. Sleep abnormalities, neuropsychiatric symptoms within the autistic and affective spectrum, eye movement abnormalities, optic nerve atrophy, sensorineural hearing loss and Rett-like hand stereotypies have also been reported in a subset of patients (Hayflick *et al.*, 2013; Ohba *et al.*, 2014; Rathore *et al.*, 2014; Verhoeven *et al.*, 2014). Distinctive MRI changes allow a diagnosis in many cases (Kruer *et al.*, 2012): iron accumulation is detectable on regular T<sub>2</sub> sequences in the substantia nigra even at an early disease stage, while detecting iron deposits in the globus pallidum requires other techniques such as gradient-echo or T<sub>2</sub>\*-weighted sequences. Hyperintensity on T<sub>1</sub>-weighted axial images with a central band of hypointense signal has been reported as a pathognomonic feature of BPAN (Kruer *et al.*, 2012; Ichinose *et al.*, 2014; Ozawa *et al.*, 2014). Cerebral atrophy, or less commonly cerebellar atrophy, and basal ganglia calcification (Van Goethem *et al.*, 2014) can also be seen. Post-mortem examination of two adult cases of BPAN revealed extensive and widespread accumulation of hyperphosphorylated tau protein in the form of neurofibrillary tangles, arguing that BPAN shares neuropathological features with classic degenerative tauopathies such as Alzheimer’s disease (Hayflick *et al.*, 2013; Paudel *et al.*, 2015). BPAN is inevitably fatal with

current therapeutic strategies being targeted at symptomatic relief of parkinsonian features, dystonia and seizures.

Using exome sequencing, two independent groups recently uncovered mutations in the *WDR45* gene as the genetic cause of BPAN (Haack *et al.*, 2012; Saitsu *et al.*, 2013). *WDR45*, also known as *WIPI4*, is located on the X-chromosome and is one of the four mammalian homologues of the core autophagy gene *epg-6* in *C. elegans* (Proikas-Cezanne *et al.*, 2004; Lu *et al.*, 2011). *WDR45* encodes a WD repeat protein, a superfamily of proteins that is characterized by repeating units with a conserved core of ~40 amino acids that terminate with tryptophan-aspartic acid (WD) residues. WD40 proteins have a highly symmetrical beta-propeller tertiary structure that enables them to regulate the assembly of multiprotein complexes by providing a stable anchoring platform for simultaneous and reversible protein–protein interactions (Stirnemann *et al.*, 2010). Based on these properties, WD-repeat proteins are key components of many essential biological functions and pathways, including autophagy, signal transduction pathways, transcriptional regulation, cell cycle control, apoptosis, and vesicular trafficking (Stirnemann *et al.*, 2010).

*WDR45*, the WD-repeat protein mutated in BPAN, interacts with autophagy proteins Atg2 and Atg9 to regulate key steps during autophagosome formation and elongation (Behrends *et al.*, 2010; Lu *et al.*, 2011). Hence, depletion of *WDR45* in mammalian cells leads to the accumulation of autophagosomes and early autophagic vesicles (Behrends *et al.*, 2010; Lu *et al.*, 2011). Investigating the effect of *WDR45* mutations in lymphoblast cell lines derived from BPAN patients, Saitsu *et al.* (2013) found that levels of *WDR45* protein were strongly diminished, suggesting that the mutant protein is structurally unstable and undergoes rapid degradation (Saitsu *et al.*, 2013). Subsequently, autophagic flux is impaired, leading to an accumulation of abnormal and immature autophagic vacuoles. The latter was confirmed by showing that accumulating abnormal autophagosome precursors stain for both Atg9A and LC3, indicating improper autophagosome formation, since, under normal conditions, Atg9A only transiently associates with the autophagosome formation site and is absent from mature LC3-positive autophagosomes (Orsi *et al.*, 2012). In summary, findings in cells from BPAN patients indicate that autophagy is perturbed at an early stage (Table 1 and Fig. 2), suggesting that autophagy dysfunction might account for the neurological sequelae of the disease. Interestingly, although BPAN is clinically thought to primarily affect the brain, *WDR45* is expressed in many human tissues with the highest expression found in skeletal muscle (Proikas-Cezanne *et al.*, 2004). A muscle phenotype, however, remains to be formally investigated. The selective degeneration of neuronal populations may be explained by cell-type-specific differences in autophagy and tolerance to changes in this pathway. Neurons as non-dividing, highly differentiated cells heavily rely on intracellular degradation pathways to maintain homeostasis and normal structure

and function. This is exemplified by brain-specific knockout mice of core autophagy genes showing a striking neurodegenerative phenotype similar to that found in ageing-related neurodegenerative diseases (Hara *et al.*, 2006; Komatsu *et al.*, 2006). Because mice globally deficient in autophagy die shortly after birth (Kuma *et al.*, 2004; Komatsu *et al.*, 2005), *WDR45* mutations in affected human males might be inevitably lethal at an early stage. Recently reported conditional CNS-specific *WDR45* knockout mice (Nes-*WDR45*<sup>fl/y</sup>) show axonal pathology with swollen axons and accumulation of autophagy substrates p62 and ubiquitin. Although neither neurodegeneration nor iron deposition are prominent phenotypes, Nes-*WDR45*<sup>fl/y</sup> mice, at the behavioural level, exhibit subtle motor coordination deficits and poor learning and memory, suggesting deficits in neuronal circuit formation or neurotransmission (Zhao *et al.*, 2015). Another interesting lead into the pathogenesis of BPAN comes from the recent appreciation of the role of autophagy in iron metabolism. The bioavailability of intracellular iron is critically controlled through the delivery of ferritin to autophagosomes and lysosomes for degradation (ferritinophagy), allowing release of iron into the cytoplasm (Kidane *et al.*, 2006; Asano *et al.*, 2011; Mancias *et al.*, 2014). Hence, deficits in ferritinophagy could disturb iron homeostasis, potentially contributing to the iron storage phenotype seen in NBIA that seems to confer selectivity for vulnerable brain regions.

In summary, BPAN, the second discussed congenital disorder of autophagy, is of particular importance as this disease, for the first time, confirms that genetic deficits in the autophagy pathway are indeed associated with early-onset neurodegeneration in humans (Saitsu *et al.*, 2013). This further supports a role for autophagy in the pathogenesis of an expanding list of sporadic ageing-related neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and others (Ebrahimi-Fakhari *et al.*, 2012; Nixon, 2013) and may provide novel insights into the role of autophagy in iron metabolism.

## **SNX14-associated autosomal-recessive cerebellar ataxia and intellectual disability syndrome**

The childhood-onset autosomal-recessive cerebellar ataxias are a group of heterogeneous inherited diseases characterized by progressive cerebellar atrophy and prominent Purkinje cell degeneration. Next-generation sequencing has allowed a genetic and molecular resolution of a number of entities and holds great promise to facilitate an early diagnosis in many cases (Nemeth *et al.*, 2013; Pyle *et al.*, 2015). Recently, two independent groups identified truncating loss-of-function mutations in the sorting nexin gene, *SNX14*, as the cause of a clinically distinct autosomal-recessive cerebellar ataxia syndrome (Thomas *et al.*, 2014; Akizu *et al.*, 2015). Patients with bi-allelic

*SNX14* mutations present with globally delayed development, hypotonia, absent speech, progressive cerebellar atrophy and ataxia, seizures, and a storage disease phenotype consisting of coarse facial features, macroglossia, hypertrichosis, kyphoscoliosis, sensorineural hearing loss, and hepatosplenomegaly in a few cases (Table 1) (Sousa *et al.*, 2014; Thomas *et al.*, 2014; Akizu *et al.*, 2015). On clinical grounds, these manifestations suggest overlapping disease mechanisms with lysosomal storage diseases with prominent involvement of the cerebellum such as Niemann-Pick disease type C (NP-C) or Tay-Sachs disease. Indeed, mutant *SNX14* patient fibroblasts contain enlarged lysosomes (Thomas *et al.*, 2014; Akizu *et al.*, 2015), providing a rationale to further investigate the role of *SNX14* in lysosomal turnover.

*SNX14* encodes a protein of the sorting nexin family that contains two putative transmembrane domains (Mas *et al.*, 2014). Through the RGS (regulator of G protein signalling) domain, *SNX14* attenuates *Gas*-coupled G protein-coupled receptor signalling. Through its PX (phox homology) domain *SNX14* binds membrane phosphatidylinositol residues and is involved in intracellular trafficking. Phospholipids on membranes of different organelles provide a platform for recruiting factors that mediate membrane turnover and fusion. With regards to the autophagy pathway, this is important for key membrane fusion events such as the fusion of phosphatidylinositol 3-phosphate coated autophagosomes with phosphatidylinositol (3,5)-bisphosphate carrying lysosomes (Dall'Armi *et al.*, 2013). The importance of phospholipids for autophagy is exemplified by recent studies that show key regulatory functions in the regulation of canonical (Burman and Ktistakis, 2010) and non-canonical autophagy (Vicinanze *et al.*, 2015). In addition, cardiolipins, a subtype of phospholipids localized to the inner mitochondrial membrane, serve as a crucial signal for autophagic degradation when exposed on the surface of depolarized mitochondria (Chu *et al.*, 2013). Binding to their respective phospholipid signature, *SNX14* co-localizes with the lysosome and is enriched in autophagosome containing cell fractions (Akizu *et al.*, 2015). In induced pluripotent stem cell (iPSC)-derived neuronal cells from patients with *SNX14* mutations, lysosomes are increased in size and autophagosome clearance is impaired (Akizu *et al.*, 2015). This pattern closely resembles findings in certain lysosomal storage diseases (Ebrahimi-Fakhari *et al.*, 2014). Knockdown of *snx14* in a zebrafish model confirmed these observations and linked them to progressive Purkinje cell loss, suggesting neuronal cell death secondary to impaired autophagy (Akizu *et al.*, 2015). Purkinje cells are exquisitely sensitive to autophagy impairment and perturbations of lysosomal metabolism (Hara *et al.*, 2006; Komatsu *et al.*, 2006), which may be attributable to their size, high metabolic activity, and complex dendritic architecture. Not surprisingly, post-mortem neuropathological assessment showed a near complete absence of Purkinje cells in an affected individual with bi-allelic *SNX14* mutations (Akizu *et al.*, 2015).

*SNX14*-associated autosomal-recessive cerebellar ataxia is thus a further disease that links autophagy to neurodegeneration and highlights the importance of autophagy for Purkinje cell function and survival. Given the emerging links between cerebellar circuit dysfunction and syndromic forms of autism-spectrum disorder (Tsai *et al.*, 2012), it is interesting to note that the majority of reported patients with *SNX14* mutations show autistic-like behaviour (Akizu *et al.*, 2015).

## Hereditary spastic paraplegia: SPG11 (SPG11), SPG15 (ZFYVE26) and SPG49 (TECPR2)

Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous group of neurodegenerative diseases that occurs at a prevalence of about 3–10 cases per 100 000 individuals (Salinas *et al.*, 2008; Blackstone, 2012). All forms of HSP share the unifying feature of distal axonal degeneration in the corticospinal tracts (Lo Giudice *et al.*, 2014). In some cases, ascending spinal tracts such as the gracile fasciculus and the spinocerebellar tracts may also be affected. Clinically, degeneration of the corticospinal tracts leads to progressive weakness and spasticity of the lower limbs. Additional manifestations in the various forms of HSP described to date range from congenital brain abnormalities such as agenesis of the corpus callosum or cerebellar dysplasia, to signs of neuronal dysfunction and neurodegeneration such as cognitive impairment, ataxia, optic nerve atrophy, epilepsy, and peripheral neuropathy (Lo Giudice *et al.*, 2014). Given the unifying feature of axonal degeneration of the long tracts, the HSPs serve as a genetically tractable model for identifying pathways that ensure axonal function and survival. Covering all modes of inheritance, more than 70 disease loci and 50 spastic paraplegia genes have been identified to date. These genes map to multiple cellular pathways and processes, including endoplasmic reticulum function, vesicle formation, membrane trafficking, mitochondrial function, lipid metabolism, myelination, axonal transport and autophagy (Blackstone, 2012; Lo Giudice *et al.*, 2014; Noreau *et al.*, 2014). Here, we discuss SPG11, SPG15 and SPG49, three autosomal recessive forms of HSP characterized by autophagy dysfunction.

SPG11 (OMIM #604360) and SPG15 (OMIM #270700) are the most prevalent forms of autosomal recessive HSP with thin corpus callosum (Goizet *et al.*, 2009; Schule *et al.*, 2009; Pensato *et al.*, 2014). The clinical phenotype in SPG11 and SPG15 is often indistinguishable (Table 1) and an accurate diagnosis therefore requires genetic testing (Schule *et al.*, 2009). Patients with SPG11 or SPG15 often present with Kjellin syndrome, in which early-onset spastic paraplegia is accompanied by intellectual disability, pigmentary retinopathy, cerebellar dysfunction, and distal amyotrophy in the first or second decade of life (Kjellin, 1959). Parkinsonism is also sometimes observed.



Following linkage to the SPG11 locus on chromosome 15q (Martinez Murillo *et al.*, 1999; Shibasaki *et al.*, 2000), the gene for SPG11, *SPG11*, and its protein product spatacsin were identified (Stevanin *et al.*, 2007, 2008).

For SPG15, Hughes *et al.* (2001) were first to identify the causative gene locus on chromosome 14q from two Irish families with autosomal-recessive Kjellin syndrome before Hanein *et al.* (2008) pinpointed the causal gene to *ZFYVE26*, which encodes the zinc-finger protein spastizin. Over 100 mutations in *SPG11* and >20 mutations in *ZFYVE26* have been identified in patients, the majority of which are truncating, nonsense mutations (Goizet *et al.*, 2009; Pensato *et al.*, 2014).

Spastizin is a 285 kDa protein comprising of a zinc finger domain, a FYVE domain, and a leucine zipper domain (Hanein *et al.*, 2008). FYVE-domain containing proteins bind phosphatidylinositol 3-phosphate, suggesting a likely function of spastizin in membrane trafficking (Kutateladze and Overduin, 2001). Spastizin is expressed most abundantly in motor cortex, hippocampus, cerebellum, pons and spinal cord, particularly during development (Hanein *et al.*, 2008; Murmu *et al.*, 2011; Khundadze *et al.*, 2013). Intracellularly, spastizin has been observed to co-localize with a variety of structures and organelles, including endosomes and the endoplasmic reticulum and, to a likely lesser extent, microtubules, mitochondria, and the nucleus (Hanein *et al.*, 2008; Murmu *et al.*, 2011; Khundadze *et al.*, 2013; Vantaggiato *et al.*, 2013).

*Zfyve26* knockout mice develop normally but by 12 months of age acquire a spastic and ataxic gait disorder accompanied by neuron loss in the motor cortex and the cerebellum, thus recapitulating the clinical phenotype of patients with HSP (Khundadze *et al.*, 2013). Zebrafish models generated by morpholino-mediated knockdown of *zfyve26* also show motor neuron growth impairment and morphological abnormalities (Martin *et al.*, 2012). Interestingly, knockdown of *SPG11* results in a strikingly similar phenotype (Martin *et al.*, 2012), providing genetic evidence that spastizin and spatacsin might act as part of the same pathway as previously suggested by physical interaction of the two proteins (Slabicki *et al.*, 2010) and overlapping clinical features in SPG15 and SPG11 patients (Boukhris *et al.*, 2008, Schule *et al.*, 2009).

At the cellular level, high-density LAMP1-positive membrane-bound vesicles and lipopigment accumulate in neurons of *Zfyve26* knockout mice and precede neurodegenerative changes (Khundadze *et al.*, 2013). Enlarged lysosomes are readily visible in fibroblasts derived from SPG15 patients (Renvoise *et al.*, 2014), similarly suggesting deficits in the autophagy-lysosomal and/or endosomal-lysosomal pathway. Vantaggiato *et al.* (2013) recently provided an important lead by identifying an interaction between spastizin and the beclin 1-UVRAG-Rubicon complex of the autophagy pathway (Vantaggiato *et al.*, 2013) (Fig. 2). As discussed above, beclin 1 has a multifaceted role in autophagy: in association with Atg14L and Ambra1, the beclin 1-VPS34-VPS15 class III

phosphatidylinositol 3-kinase complex is involved in autophagosome formation by regulating phosphatidylinositol 3-phosphate synthesis; separately, when interacting with cofactors UVRAG and Bif-1, beclin 1-VPS34-VPS15 induces autophagosome maturation and endosome fusion. Finally, Rubicon, in complex with UVRAG and beclin 1-VPS34-VPS15, functions as a negative regulator of autophagy (Liang *et al.*, 2006; Itakura *et al.*, 2008; Matsunaga *et al.*, 2009; Zhong *et al.*, 2009; Kang *et al.*, 2011). Spastizin interacts with the beclin 1-UVRAG-Rubicon multiprotein complex and is thus involved in autophagosome maturation (Vantaggiato *et al.*, 2013, 2014). Mutations in spastizin disrupt its interaction with beclin 1 and inhibit autophagosome maturation, leading to an accumulation of immature autophagosomes in fibroblasts and lymphoblasts from SPG15 patients (Vantaggiato *et al.*, 2013). RNA-interference-mediated knockdown of spastizin in cultured neurons was shown to yield similar results. In addition, reduced co-localization of LC3 and LAMP1 was noted in basal and autophagy-promoting conditions, indicating a block in autophagosome-lysosome fusion (Vantaggiato *et al.*, 2013). Recently, pathogenic alterations of autophagy and lysosomal function in SPG15 have been further confirmed by showing that spastizin and the SPG11 protein spatacsin are instrumental for the reformation of autophagic lysosomes, a recycling pathway that generates new lysosomes (Chang *et al.*, 2014; Varga *et al.*, 2015). This mechanism of lysosome biogenesis maintains a pool of lysosomes that are competent to fuse with autophagosomes in order to create new autolysosomes (Yu *et al.*, 2010). Spastizin forms a complex with spatacsin and is targeted to lysosomes through spastizin's FYVE domain. Loss of either spastizin or spatacsin results in accumulation of enlarged autolysosomes, which is reversible by reintroducing wild-type spastizin. Similarly, accumulation of autophagosomes and depletion of free lysosomes is seen, suggesting a block at the autophagic lysosome reformation stage (Chang *et al.*, 2014; Varga *et al.*, 2015). Taken together, disruption of the critical steps of autophagosome maturation and lysosomal biogenesis contributes to the neurodegeneration seen in SPG15 and related forms of HSP such as SPG11.

Oz-Levi *et al.* (2012) identified a new form of apparently autosomal-recessive HSP, SPG49 (OMIM #615031), in three Jewish Bukharian families. Affected individuals present with distinct dysmorphic features, delayed development and muscular hypotonia at around 2 years of age before phenotypically progressing to intellectual disability, spastic paraplegia, rigidity, dysarthria and ataxia (Oz-Levi *et al.*, 2012). Severe central apnoea and gastroesophageal reflux disease are additional features of the disease. Exome sequencing revealed a single and likely causal variant (c.3416delT) in the tectonin  $\beta$ -propeller containing protein 2 (*TECPR2*) gene (also *KIAA0329*), resulting in a premature stop codon (Oz-Levi *et al.*, 2012). The truncated protein resulting from the putative pathogenic c.3416delT mutation undergoes rapid degradation, indicating a loss-



of-function mechanism. Through high-throughput proteomic analysis of the autophagy pathway, TECPR2 has been established to be a binding partner of the mammalian Atg8 protein family, including LC3, and a probable positive regulator of autophagosome formation (Behrends *et al.*, 2010). Using fibroblasts of affected SPG49 patients and siRNA-mediated knockdown of TECPR2 in cultured cell lines, loss of TECPR2 was found to result in a decreased number of autophagosomes and reduced delivery of LC3 and p62 for lysosomal degradation. These results suggest that SPG49 pathology involves a significant, though not entirely complete, impairment of the autophagy pathway (Oz-Levi *et al.*, 2012). Providing insights into the mechanism of defective autophagy in SPG49, a recent study showed that TECPR2 is involved in maintaining functional endoplasmic reticulum exit sites, which may serve as scaffolds for the formation of autophagosomes (Stadel *et al.*, 2015).

## Autophagy in mTOR-associated neurodevelopmental diseases

Pathways that monitor nutrient or amino acid supply (mTORC1 pathway) and cellular ATP-levels (AMPK pathway) critically control autophagy. A central regulator of cellular metabolism, the ubiquitously expressed serine/threonine kinase mTORC1 facilitates anabolic processes that supply the basic building blocks for cell growth, differentiation and proliferation. Not surprisingly, mTORC1 also blocks catabolic pathways such as autophagy via transcriptional and post-translational mechanisms. Conversely, conditions known to induce autophagy, such as for example starvation or growth factor deprivation, effectively reduce mTORC1 activity. Critical targets of mTORC1 that mediate its effect on autophagy are TFEB, regulating autophagy at the transcriptional level, and the ULK1/2 complex, AMBRA1 and the ATG14L-associated VPS34 complex, proteins that are involved in the autophagy initiation step as discussed above (Fig. 2). mTORC1 is important for disorders of autophagy for two reasons: firstly, genetic deficits of the mTOR pathway will almost certainly provoke changes in autophagy, and therefore ‘mTORopathies’ can be regarded as ‘congenital disorders of autophagy regulation,’ and secondly and perhaps most importantly, mTORC1 inhibitors, including drugs currently approved for a variety of conditions, are clinically available inducers of autophagy. An example for an mTOR-associated neurodevelopmental disease with defective autophagy is tuberous sclerosis complex (TSC). In this multisystem disease, loss-of-function mutations in *TSC1* or *TSC2* lead to a constitutive activation of the mTORC1 pathway (Lipton and Sahin, 2014; DiMario *et al.*, 2015). Overactive mTORC1 is the key pathogenic molecular mechanism in TSC and provides the scientific rationale for the use of mTORC1 inhibitors to treat this disease (Julich and Sahin, 2014; Ebrahimi-Fakhari and Sahin, 2015). Autophagy deficits in TSC have been

implicated as contributors to epileptogenesis (McMahon *et al.*, 2012), brain malformations (Yasin *et al.*, 2013), tumour formation (Liang *et al.*, 2014), autism, and neurocognitive deficits (Tang *et al.*, 2014) by impacting neuronal metabolism and synaptic signalling. Understanding autophagy dysfunction as a downstream event of *TSC1* or *TSC2* mutations is important and might lead to novel therapeutic targets. mTOR-associated diseases therefore highlight the close ties of the autophagy pathway to other fundamental signalling cascades and thus provide an opportunity to investigate the role of dysregulated autophagy in neurodevelopmental diseases.

## Autophagy in lysosomal storage diseases

Progressive accumulation of undigested macromolecules in lysosomes is the hallmark feature of lysosomal storage diseases, a group of nearly 60 different diseases caused by mutations in genes encoding for lysosomal enzymes or membrane proteins (Boustany, 2013; Platt, 2014). Not surprisingly, impaired lysosomal metabolism has many effects on upstream pathways that mediate cargo delivery to the lysosomes. Recent studies have documented impaired autophagy in patient samples and disease models of many different lysosomal storage diseases (Lieberman *et al.*, 2012; Ebrahimi-Fakhari *et al.*, 2014). These deficits in autophagy are likely independent and significant contributors to neurodegeneration and other neuronal and non-neuronal disease manifestations, as convincingly illustrated in Niemann-Pick disease Type C (NP-C) models, where a block in autophagic flux and an accumulation of autophagosomes secondary to impaired maturation has been documented (Elrick *et al.*, 2012; Maetzel *et al.*, 2014; Sarkar *et al.*, 2014). Interestingly, re-expression of NPC1, the protein mutated in NP-C, restored autophagy deficits in NPC1-deficient cells, and pharmacological stimulation of autophagy had a cell-protective effect. The latter concept was recently confirmed in iPSC-derived hepatic and neuronal cells from NP-C patients, where mTOR-independent autophagy inducers, identified through a large-scale screening approach for small molecules, promoted cell viability (Maetzel *et al.*, 2014). Combining compounds that mobilize lysosomal cholesterol, such as 2-hydroxypropyl- $\beta$ -cyclodextrin (Vite *et al.*, 2015) with inducers of autophagy is thus a promising novel therapeutic approach. Glycogen storage disease type II or Pompe disease, although primarily a severe myopathy, is another important case for the potential therapeutic role of autophagy. Genetic approaches that employ TFEB to enhance autophagic flux have shown great promise in proof-of-principle *in vitro* and *in vivo* studies (Spampanato *et al.*, 2013). Future investigations for small molecules or effective genetic strategies that would render TFEB a clinically approachable target will prove or disprove the clinical utility of these findings for lysosomal storage diseases.

## Unifying features in congenital disorders of autophagy

Major differences in the clinical manifestations of different congenital disorders of autophagy are obvious. This clinical heterogeneity may result from the fact that genes and proteins mutated in individual diseases map to different stages of the pathway and may lead to different degrees of residual autophagic activity. Clinical manifestations are also likely influenced by tissue-specific expression of autophagy proteins during and after development, differences in susceptibility of tissues to deficits in autophagy, a different degree of autophagic flux and metabolic activity in different cell types, and compensatory mechanisms or the existence of genetic or environmental modifiers. Identification and molecular delineation of novel congenital deficits of autophagy in humans will provide an understanding of these factors and will thus provide unique insights into the role of autophagy in human development and disease. Despite a variable clinical expression, a few unifying features are appreciable in congenital disorders of autophagy (Box 1). This includes, for example, a clinical manifestation in multiple organ systems with predominant involvement of the nervous system, an onset in childhood or adolescence, a progressive disease course with neurodegenerative features, and a ‘storage phenotype’ (Box 1). An involvement of the long white matter tracts as seen, for example, with agenesis or progressive thinning of the corpus callosum is another intriguing common denominator. How disruption of neuronal autophagy affects higher brain functions remains an open question and has implications for complex disease manifestations such as intellectual disability or epilepsy.

## Restoring deficits in autophagy as a therapeutic approach

Pharmacological approaches that modulate autophagy have received increasing attention as a potential therapy for a broad range of autophagy-associated diseases (Table 2) (Ebrahimi-Fakhari *et al.*, 2012; Rubinsztein *et al.*, 2012; Nixon, 2013). Many small molecule inducers of autophagy act through the mTOR pathway (e.g. rapamycin and rapalogs), but mTOR-independent regulators also exist (e.g. carbamazepine or lithium, which signal through inositol 1,4,5-trisphosphate; Table 2). Target specificity is a tremendous challenge for drug development, and many available compounds have autophagy-independent off-target effects. Not surprisingly, a number of known autophagy modulators are currently in clinical trials or in clinical use for indications other than autophagy induction. It is imperative to learn how these compounds affect autophagy and whether existing drugs with an extensive clinical safety profile could be readily used to target autophagy. This concerns, for example, the

### Box 1 Unifying clinical characteristics of congenital disorders of autophagy

- Disease onset in early childhood/adolescence
- Prominent nervous system involvement
  - Multiple brain regions involved
  - Long white-matter tracts (corpus callosum and cortico-spinal tract) and the cerebellum (Purkinje cells) are often affected
  - Neurodegenerative phenotype with developmental regression and cognitive decline
  - Storage disease phenotype
  - Delayed development / intellectual disability, muscular hypotonia, seizures and movement disorders are common
- Often multisystem disease with additional non-neuronal manifestations (including myopathy and ophthalmic manifestations)
- Progressive disease course, often fatal

use of the antiepileptic drug carbamazepine (Hidvegi *et al.*, 2010; Maetzel *et al.*, 2014) or lysosomotropic agents such as chloroquine (Amaravadi *et al.*, 2011). Although the diseases discussed in this review are rare, the extent to which they might inform us about therapeutic targets in the autophagy pathway is significant. Based on current evidence, enhancing residual autophagy function or bypassing molecular deficits appear to be rational therapeutic approaches for congenital disorders of autophagy. The latter might be achieved by targeting the stage of the autophagy pathway that is specifically disrupted in each given disease. Understanding the biology of congenital disorders of autophagy will help to design these proposed stage-specific autophagy-targeted therapies.

iPSCs have emerged as a valuable preclinical model to study rare diseases, given that reliable animal models for these conditions are often not readily available. In addition, several protocols exist that enable differentiation into relevant cell types such as neuronal cells. These will be instrumental for understanding disease phenotypes arising from different genetic mutations in individual patients and will provide a very useful platform for high throughput screening approaches that aim to identify molecules that restore autophagy function in a given disease. Recent studies have described the generation of human iPSC lines from patients with a range of inherited diseases (Park *et al.*, 2008; Ebert *et al.*, 2009; Lee *et al.*, 2009; Marchetto *et al.*, 2010) and proof-of-principle screening studies for modulators of autophagy using iPSC are emerging (Maetzel *et al.*, 2014).

The transition from cellular and mouse models to humans will contest the potential for harnessing autophagy-based therapies. To translate potential targets into therapies, a challenge that will have to be overcome is the development of *in vivo* biomarkers to detect changes in autophagy in response to therapeutics or disease progression. This will be most effective when stage-specific methods or surrogate biomarkers become available to confirm target engagement, which will be essential to interpret outcomes in clinical trials. As with most congenital childhood-onset diseases with a clear neurodevelopmental phenotype, another concern is the optimal timing to start treatment.

**Table 2 Modulators of autophagy in neuronal disease models**

Compound	Proposed target and mechanism	Model system and selected references
Bafilomycin A1	Autophagy inhibition Inhibition of the vacuolar-type ATPase Disrupts lysosomal acidification and prevents autophagosome-lysosome fusion	Neuronal cell models: Shacka <i>et al.</i> , 2006; Bains <i>et al.</i> , 2009 Mouse models: Ebrahimi-Fakhari <i>et al.</i> , 2011; Klucken <i>et al.</i> , 2012
Carbamazepine	Autophagy induction Voltage-gated Na <sup>2+</sup> channel inhibitor Lowers inositol and inositol-1,4,5-triphosphate levels	Neuronal cell models: Williams <i>et al.</i> , 2008; Xiong <i>et al.</i> , 2011 iPSC-derived neuronal cells: Maetzel <i>et al.</i> , 2014 Mouse models: Wang <i>et al.</i> , 2012a; Li <i>et al.</i> , 2013
(Hydroxy-) Chloroquine	Autophagy inhibition Disrupts lysosomal acidification and prevents autophagosome-lysosome fusion	Neuronal cell models: Boland <i>et al.</i> , 2010 Mouse models: Ebrahimi-Fakhari <i>et al.</i> , 2011; Vodicka <i>et al.</i> , 2014
Clonidine	Autophagy induction Imidazole receptor agonist Lowers cAMP levels	Neuronal cell model: <i>D. melanogaster</i> ; zebrafish Williams <i>et al.</i> , 2008
Latrepiridine	Autophagy induction mTORC1 inhibition	Neuronal cell model, mouse models: Steele <i>et al.</i> , 2013a, 2013b
Lithium	Autophagy induction Inositol monophosphatase inhibitor Lowers inositol and inositol-1,4,5-triphosphate levels	Neuronal cell models: Sarkar <i>et al.</i> , 2005; Chang <i>et al.</i> , 2011 Mouse models: Sarkar <i>et al.</i> , 2005; Fornai <i>et al.</i> , 2008; Shimada <i>et al.</i> , 2012; Duarte-Silva <i>et al.</i> , 2014
Nilotinib	Autophagy induction Abl tyrosine kinase inhibitor Activates AMPK	Mouse models: Hebron <i>et al.</i> , 2013; Lonskaya <i>et al.</i> , 2014
Rapamycin and rapalogs	Autophagy induction mTORC1 inhibition	Neuronal cell models: Webb <i>et al.</i> , 2003; Pan <i>et al.</i> , 2008b; Williams <i>et al.</i> , 2008 Mouse models: Ravikumar <i>et al.</i> , 2004; Menzies <i>et al.</i> , 2010; Majumder <i>et al.</i> , 2011; Cortes <i>et al.</i> , 2012; Viscomi <i>et al.</i> , 2012; Jiang <i>et al.</i> , 2014 Neuronal cell model: Vingtdeux <i>et al.</i> , 2010 Mouse model: Vingtdeux <i>et al.</i> , 2010; Shu <i>et al.</i> , 2015
Resveratrol	Autophagy induction Sirtuin-1 activation Activates AMPK	Neuronal cell model: Williams <i>et al.</i> , 2008; Rose <i>et al.</i> , 2010 Mouse model: Rose <i>et al.</i> , 2010
Rilmenidine	Autophagy induction Imidazole receptor agonist Lowers cAMP levels	Neuronal cell model: Tian <i>et al.</i> , 2011; <i>D. melanogaster</i> : Sarkar <i>et al.</i> , 2007b
SMER28 and other SMER	Autophagy induction Unknown mechanism, likely mTOR-independent	Neuronal cell model: Tian <i>et al.</i> , 2011; <i>D. melanogaster</i> : Sarkar <i>et al.</i> , 2007b
Trehalose	Autophagy induction Chemical chaperone	Neuronal cell model: Sarkar <i>et al.</i> , 2007a Mouse models: Rodriguez-Navarro <i>et al.</i> , 2010; Schaeffer <i>et al.</i> , 2012; Castillo <i>et al.</i> , 2013; Zhang <i>et al.</i> , 2014; He <i>et al.</i> , 2015; Li <i>et al.</i> , 2015 Neuronal cell model, <i>D. melanogaster</i> : Williams <i>et al.</i> , 2008
Valproate	Autophagy induction Myo-inositol-3-phosphate synthase inhibitor Lowers inositol and inositol-1,4,5-triphosphate levels	Neuronal cell model, <i>D. melanogaster</i> : Williams <i>et al.</i> , 2008
Verapamil (and other Ca <sup>2+</sup> -channel blockers)	Autophagy induction L-type Ca <sup>2+</sup> -channel antagonist Lowers intracellular calcium levels	Neuronal cell model, <i>D. melanogaster</i> ; zebrafish: Williams <i>et al.</i> , 2008

Along the same lines, it remains to be seen whether existing lesions, such as for example iron storage in the basal ganglia of BPAN patients, are reversible by correcting autophagy deficits.

## Conclusions

Genetic disruption of the autophagy–lysosomal pathway, a fundamental metabolic pathway, results in a new and diverse group of multisystem diseases. We therefore argue that based on their shared genetic and molecular characteristics, these should be collectively termed ‘congenital disorders of autophagy’, a novel subclass within the field of

inborn errors of metabolism. In the past 2 years alone, next-generation sequencing technologies have allowed for the identification of a number of pathogenic mutations in core autophagy genes and will likely continue to reveal novel single gene disorders of this crucial cellular pathway. Bridging the gap between the identification of causative genes to the delineation of molecular disease mechanisms is an upcoming challenge. Development of disease models, such as those generated through iPSC technology, will allow us to gain insights into potential therapeutic targets and will yield novel therapies. Insights into congenital diseases of autophagy may be important to a wide spectrum of more common sporadic diseases with defective autophagy.

## Acknowledgements

The authors thank R. Friedman (Boston Children's Hospital, Translational Neuroscience Center) for help with database queries.

## Funding

D.E.-F. acknowledges support from the Graduate Academy of the University of Heidelberg, the Young Investigator Award Program at Ruprecht-Karls-University Heidelberg Faculty of Medicine, the Daimler and Benz Foundation (Daimler und Benz Stiftung, Ladenburg, Germany) and the Reinhard-Frank Foundation (Reinhard-Frank-Stiftung, Hamburg, Germany). A.S. is supported by a scholarship from the German National Academic Foundation (Studienstiftung des Deutschen Volkes e.V.). L.W. is supported by the Young Investigator Award Program at Ruprecht-Karls-University Heidelberg Faculty of Medicine. J.L. received support from the Medical Scientist Training Program from the National Institute of General Medical Sciences (T32GM007753). G.F.H. received generous support from the Dietmar Hopp Stiftung (St. Leon-Rot, Germany). H.J. acknowledges support from the Myotubular Trust, United Kingdom. M.S. is supported by NIH (U01 NS082320, P20 NS080199, U54NS092090, P30 HD018655), Nancy Lurie Marks Family Foundation, Boston Children's Hospital Translational Research Program. The Developmental Synaptopathies Consortium (U54NS092090) is a part of the National Center for Advancing Translational Sciences (NCATS) Rare Diseases Clinical Research Network (RDCRN). RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS, funded through collaboration between NCATS, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke and National Institute of Child Health and Human Development.

The funding agencies had no role in the design, preparation or writing of this manuscript.

## Conflict of interest

D.E.-F. and L.W. report receiving travel grants from Actelion Pharmaceuticals for attending an international scientific meeting in 2014. M.S. receives research funding from Novartis, Shire and Roche. A.S., J.L., S.B., G.F.H. and H.J. report no conflict of interest.

## Supplementary material

Supplementary material is available at *Brain* online.

## References

- Akizu N, Cantagrel V, Zaki MS, Al-Gazali L, Wang X, Rosti RO, et al. Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. *Nat Genet* 2015; 47: 528–34.
- Al-Owain M, Al-Hashem A, Al-Muhaizea M, Humaidan H, Al-Hindi H, Al-Homoud I, et al. Vici syndrome associated with unilateral lung hypoplasia and myopathy. *Am J Med Genet A* 2010; 152A: 1849–53.
- Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. *Mol Cell Biol* 2012; 32: 2–11.
- Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, et al. Principles and current strategies for targeting autophagy for cancer treatment. *Clin Cancer Res* 2011; 17: 654–66.
- Asano T, Komatsu M, Yamaguchi-Iwai Y, Ishikawa F, Mizushima N, Iwai K. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. *Mol Cell Biol* 2011; 31: 2040–52.
- Ashrafi G, Schlehe JS, LaVoie MJ, Schwarz TL. Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. *J Cell Biol* 2014; 206: 655–70.
- Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. *Cell Death Differ* 2013; 20: 31–42.
- Bains M, Florez-McClure ML, Heidenreich KA. Insulin-like growth factor-I prevents the accumulation of autophagic vesicles and cell death in Purkinje neurons by increasing the rate of autophagosome-to-lysosome fusion and degradation. *J Biol Chem* 2009; 284: 20398–407.
- Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. *Nature* 2010; 466: 68–76.
- Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J Cell Biol* 2005; 171: 603–14.
- Blackstone C. Cellular pathways of hereditary spastic paraplegia. *Annu Rev Neurosci* 2012; 35: 25–47.
- Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. *J Biol Chem* 2010; 285: 37415–26.
- Boukhris A, Stevanin G, Feki I, Denis E, Elleuch N, Miladi MI, et al. Hereditary spastic paraplegia with mental impairment and thin corpus callosum in Tunisia: SPG11, SPG15, and further genetic heterogeneity. *Arch Neurol* 2008; 65: 393–402.
- Boustany RM. Lysosomal storage diseases—the horizon expands. *Nat Rev Neurol* 2013; 9: 583–98.
- Burman C, Ktistakis NT. Regulation of autophagy by phosphatidylinositol 3-phosphate. *FEBS Lett* 2010; 584: 1302–12.
- Byrne S, Jansen L, U-King-Im JM, Siddiqui A, Lidov H, Bodi I, et al. EPG5-related Vici syndrome: a paradigm of neurodevelopmental disorders with defective autophagy. *Brain*, in press.
- Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. *Autophagy* 2013; 9: 1308–20.
- Chang J, Lee S, Blackstone C. Spastic paraplegia proteins spastizin and spatacsin mediate autophagic lysosome reformation. *J Clin Invest* 2014; 124: 5249–62.
- Chang JW, Choi H, Cotman SL, Jung YK. Lithium rescues the impaired autophagy process in CbCln3(Deltaex7/8/Deltaex7/8) cerebellar cells and reduces neuronal vulnerability to cell death via IMPase inhibition. *J Neurochem* 2011; 116: 659–68.
- Cheng XT, Zhou B, Lin MY, Cai Q, Sheng ZH. Axonal autophagosomes recruit dynein for retrograde transport through fusion with late endosomes. *J Cell Biol* 2015; 209: 377–86.



- Chiyonobu T, Yoshihara T, Fukushima Y, Yamamoto Y, Tsunamoto K, Nishimura Y, et al. Sister and brother with Vici syndrome: agenesis of the corpus callosum, albinism, and recurrent infections. *Am J Med Genet* 2002; 109: 61–6.
- Christian P, Sacco J, Adeli K. Autophagy: Emerging roles in lipid homeostasis and metabolic control. *Biochim Biophys Acta* 2013; 1831: 819–24.
- Chu CT, Ji J, Dagda RK, Jiang JF, Tyurina YY, Kapralov AA, et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. *Nat Cell Biol* 2013; 15: 1197–205.
- Cortes CJ, Qin K, Cook J, Solanki A, Mastrianni JA. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Straussler-Scheinker disease. *J Neurosci* 2012; 32: 12396–405.
- Cullup T, Dionisi-Vici C, Kho AL, Yau S, Mohammed S, Gautel M, et al. Clinical utility gene card for: Vici Syndrome. *Eur J Hum Genet* 2014; 22.
- Cullup T, Kho AL, Dionisi-Vici C, Brandmeier B, Smith F, Urry Z, et al. Recessive mutations in EPG5 cause Vici syndrome, a multi-system disorder with defective autophagy. *Nat Genet* 2013; 45: 83–7.
- Dall'Armi C, Devereaux KA, Di Paolo G. The role of lipids in the control of autophagy. *Curr Biol* 2013; 23: R33–45.
- Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. *Proc Natl Acad Sci USA* 2013; 110: E1817–26.
- del Campo M, Hall BD, Aeby A, Nassogne MC, Verloes A, Roche C, et al. Albinism and agenesis of the corpus callosum with profound developmental delay: Vici syndrome, evidence for autosomal recessive inheritance. *Am J Med Genet* 1999; 85: 479–85.
- Di Nardo A, Wertz MH, Kwiatkowski E, Tsai PT, Leech JD, Greene-Colozzi E, et al. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. *Hum Mol Genet* 2014; 23: 3865–74.
- DiMario FJ Jr, Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. *Pediatr Clin North Am* 2015; 62: 633–48.
- Dionisi Vici C, Sabetta G, Gambarara M, Vigevano F, Bertini E, Boldrini R, et al. Agenesis of the corpus callosum, combined immunodeficiency, bilateral cataract, and hypopigmentation in two brothers. *Am J Med Genet* 1988; 29: 1–8.
- Duarte-Silva S, Neves-Carvalho A, Soares-Cunha C, Teixeira-Castro A, Oliveira P, Silva-Fernandes A, et al. Lithium chloride therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease. *Cerebellum* 2014; 13: 713–27.
- Ebert AD, Yu J, Rose FF, Jr., Mattis VB, Lorson CL, Thomson JA, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature* 2009; 457: 277–80.
- Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. *J Neurosci* 2011; 31: 14508–20.
- Ebrahimi-Fakhari D, Sahin M. Autism and the synapse: emerging mechanisms and mechanism-based therapies. *Curr Opin Neurol* 2015; 28: 91–102.
- Ebrahimi-Fakhari D, Wahlster L, Hoffmann GF, Kolker S. Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases. *Pediatr Res* 2014; 75: 217–26.
- Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: curse or blessing. *Acta Neuropathol* 2012; 124: 153–72.
- Efeyan A, Comb WC, Sabatini DM. Nutrient-sensing mechanisms and pathways. *Nature* 2015; 517: 302–10.
- Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. *Science* 2011; 331: 456–61.
- Ehmke N, Parvaneh N, Krawitz P, Ashrafi MR, Karimi P, Mehdizadeh M, et al. First description of a patient with Vici syndrome due to a mutation affecting the penultimate exon of EPG5 and review of the literature. *Am J Med Genet A* 2014; 164A: 3170–5.
- Elrick MJ, Yu T, Chung C, Lieberman AP. Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease. *Hum Mol Genet* 2012; 21: 4876–87.
- Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. *Cell Res* 2014; 24: 24–41.
- Filloux FM, Hoffman RO, Viskochil DH, Jungbluth H, Creel DJ. Ophthalmologic Features of Vici Syndrome. *J Pediatr Ophthalmol Strabismus* 2014; 51: 214–20.
- Finocchi A, Angelino G, Cantarutti N, Corbari M, Bevivino E, Cascioli S, et al. Immunodeficiency in Vici syndrome: a heterogeneous phenotype. *Am J Med Genet A* 2012; 158A: 434–9.
- Fornai F, Longone P, Cafaro L, Kastschuchka O, Ferrucci M, Manca ML, et al. Lithium delays progression of amyotrophic lateral sclerosis. *Proc Natl Acad Sci USA* 2008; 105: 2052–7.
- Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex—at the crossroads of autophagy and beyond. *Trends Cell Biol* 2010; 20: 355–62.
- Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation and cancer progression. *EMBO J* 2015; 34: 856–80.
- Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. *J Biol Chem* 2009; 284: 12297–305.
- Goizet C, Boukhris A, Maltete D, Guyant-Marechal L, Truchetto J, Mundwiller E, et al. SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum. *Neurology* 2009; 73: 1111–9.
- Gomes LC, Dikic I. Autophagy in antimicrobial immunity. *Mol Cell* 2014; 54: 224–33.
- Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. *Cell* 2014; 157: 65–75.
- Haack TB, Hogarth P, Kruer MC, Gregory A, Wieland T, Schwarzmayr T, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. *Am J Hum Genet* 2012; 91: 1144–9.
- Hanein S, Martin E, Boukhris A, Byrne P, Goizet C, Hamri A, et al. Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. *Am J Hum Genet* 2008; 82: 992–1002.
- Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 2006; 441: 885–9.
- Hayflick SJ, Kruer MC, Gregory A, Haack TB, Kurian MA, Houlden HH, et al. beta-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. *Brain* 2013; 136(Pt 6): 1708–17.
- He Q, Koprach JB, Wang Y, Yu WB, Xiao BG, Brochie JM, et al. Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV alpha-synuclein rat model of Parkinson's disease. *Mol Neurobiol* 2015.
- Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. *Hum Mol Genet* 2013; 22: 3315–28.
- Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. *Science* 2010; 329: 229–32.
- Horvath R. Brain iron takes off: a new propeller protein links neurodegeneration with autophagy. *Brain* 2013; 136(Pt 6): 1687–91.
- Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. *Mol Biol Cell* 2009; 20: 1981–91.

- Huang J, Brumell JH. Bacteria-autophagy interplay: a battle for survival. *Nat Rev Microbiol* 2014; 12: 101–14.
- Hughes CA, Byrne PC, Webb S, McMonagle P, Patterson V, Hutchinson M, et al. SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q. *Neurology* 2001; 56: 1230–3.
- Ichinose Y, Miwa M, Onohara A, Obi K, Shindo K, Saitsu H, et al. Characteristic MRI findings in beta-propeller protein-associated neurodegeneration (BPAN). *Neurol Clin Pract* 2014; 4: 175–7.
- Itakura E, Kishi C, Inoue K, Mizushima N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. *Mol Biol Cell* 2008; 19: 5360–72.
- Jiang T, Yu JT, Zhu XC, Zhang QQ, Cao L, Wang HF, et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. *Neuropharmacology* 2014; 85: 121–30.
- Jo EK, Yuk JM, Shin DM, Sasakawa C. Roles of autophagy in elimination of intracellular bacterial pathogens. *Front Immunol* 2013; 4: 97.
- Julich K, Sahin M. Mechanism-based treatment in tuberous sclerosis complex. *Pediatr Neurol* 2014; 50: 290–6.
- Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. *Mol Biol Cell* 2009; 20: 1992–2003.
- Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. *Cell Death Differ* 2011; 18: 571–80.
- Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. *Trends Cell Biol* 2012; 22: 407–17.
- Khundadze M, Kollmann K, Koch N, Biskup C, Nietzsche S, Zimmer G, et al. A hereditary spastic paraplegia mouse model supports a role of ZFYVE26/SPASTIZIN for the endolysosomal system. *PLoS Genet* 2013; 9: e1003988.
- Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity. *Am J Physiol Cell Physiol* 2006; 291: C445–55.
- Kim J, Kim YC, Fang C, Russell RC, Kim JH, Fan W, et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. *Cell* 2013; 152: 290–303.
- Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* 2011; 13: 132–41.
- Kjellin K. Familial spastic paraplegia with amyotrophy, oligophrenia, and central retinal degeneration. *Arch Neurol* 1959; 1: 133–40.
- Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012; 8: 445–544.
- Klionsky DJ, Baehrecke EH, Brumell JH, Chu CT, Codogno P, Cuervo AM, et al. A comprehensive glossary of autophagy-related molecules and processes (2nd edition). *Autophagy* 2011; 7: 1273–94.
- Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E, et al. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. *Autophagy* 2012; 8: 754–66.
- Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 2006; 441: 880–4.
- Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell* 2007a; 131: 1149–63.
- Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. *J Cell Biol* 2005; 169: 425–34.
- Komatsu M, Wang QJ, Holstein GR, Friedrich VL Jr, Iwata J, Kominami E, et al. Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. *Proc Natl Acad Sci USA* 2007b; 104: 14489–94.
- Kruer MC, Boddart N, Schneider SA, Houlden H, Bhatia KP, Gregory A, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. *AJNR Am J Neuroradiol* 2012; 33: 407–14.
- Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, et al. The role of autophagy during the early neonatal starvation period. *Nature* 2004; 432: 1032–6.
- Kutateladze T, Overduin M. Structural mechanism of endosome docking by the FYVE domain. *Science* 2001; 291: 1793–6.
- Lamb CA, Yoshimori T, Tooze SA. The autophagosome: origins unknown, biogenesis complex. *Nat Rev Mol Cell Biol* 2013; 14: 759–74.
- Lavandro S, Troncoso R, Rothermel BA, Martinet W, Sadoshima J, Hill JA. Cardiovascular autophagy: Concepts, controversies, and perspectives. *Autophagy* 2013; 9: 1455–66.
- Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature* 2009; 461: 402–6.
- Li L, Zhang S, Zhang X, Li T, Tang Y, Liu H, et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-beta pathology in a mouse model of Alzheimer's disease. *Curr Alzheimer Res* 2013; 10: 433–41.
- Li Y, Guo Y, Wang X, Yu X, Duan W, Hong K, et al. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. *Neuroscience* 2015; 298: 12–25.
- Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. *Nat Cell Biol* 2006; 8: 688–99.
- Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *J Exp Med* 2014; 211: 2249–63.
- Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A. Autophagy in lysosomal storage disorders. *Autophagy* 2012; 8: 719–30.
- Lipton JO, Sahin M. The neurology of mTOR. *Neuron* 2014; 84: 275–91.
- Liu K, Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. *Cell Death Differ* 2013; 20: 3–11.
- Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlandi A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. *Exp Neurol* 2014; 261: 518–39.
- Lonskaya I, Hebron ML, Desforges NM, Schachter JB, Moussa CE. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. *J Mol Med (Berl)* 2014; 92: 373–86.
- Lu Q, Yang P, Huang X, Hu W, Guo B, Wu F, et al. The WD40 repeat PtdIns(3)P-binding protein EPG-6 regulates progression of omegasomes to autophagosomes. *Dev Cell* 2011; 21: 343–57.
- Maday S, Holzbaur EL. Autophagosome biogenesis in primary neurons follows an ordered and spatially regulated pathway. *Dev Cell* 2014; 30: 71–85.
- Maday S, Wallace KE, Holzbaur EL. Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. *J Cell Biol* 2012; 196: 407–17.
- Maetzel D, Sarkar S, Wang H, Abi-Mosleh L, Xu P, Cheng AW, et al. Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPSC cells. *Stem Cell Reports* 2014; 2: 866–80.
- Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. *PLoS One* 2011; 6: e25416.
- Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. *Nature* 2014; 509: 105–9.

- Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* 2010; 143: 527–39.
- Mari M, Griffith J, Rieter E, Krishnappa L, Klionsky DJ, Reggiori F. An Atg9-containing compartment that functions in the early steps of autophagosome biogenesis. *J Cell Biol* 2010; 190: 1005–22.
- Martin E, Yanicostas C, Rastetter A, Naini SM, Maouedj A, Kabashi E, et al. Spatacsin and spastizin act in the same pathway required for proper spinal motor neuron axon outgrowth in zebrafish. *Neurobiol Dis* 2012; 48: 299–308.
- Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. *Autophagy* 2012; 8: 903–14.
- Martinez Murillo F, Kobayashi H, Pegoraro E, Galluzzi G, Creel G, Mariani C, et al. Genetic localization of a new locus for recessive familial spastic paraparesis to 15q13-15. *Neurology* 1999; 53: 50–6.
- Mas C, Norwood SJ, Bugarcic A, Kinna G, Leneva N, Kovtun O, et al. Structural basis for different phosphoinositide specificities of the PX domains of sorting nexins regulating G-protein signaling. *J Biol Chem* 2014; 289: 28554–68.
- Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N, et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. *Nat Cell Biol* 2009; 11: 385–96.
- McClelland V, Cullup T, Bodi I, Ruddy D, Buj-Bello A, Biancalana V, et al. Vici syndrome associated with sensorineural hearing loss and evidence of neuromuscular involvement on muscle biopsy. *Am J Med Genet A* 2010; 152A: 741–7.
- McMahon J, Huang X, Yang J, Komatsu M, Yue Z, Qian J, et al. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. *J Neurosci* 2012; 32: 15704–14.
- Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. *Brain* 2010; 133(Pt 1): 93–104.
- Meyer E, Kurian MA, Hayflick SJ. Neurodegeneration with brain iron accumulation: genetic diversity and pathophysiological mechanisms. *Annu Rev Genomics Hum Genet* 2015; 16:257–79.
- Miyata R, Hayashi M, Sato H, Sugawara Y, Yui T, Araki S, et al. Sibling cases of Vici syndrome: sleep abnormalities and complications of renal tubular acidosis. *Am J Med Genet A* 2007; 143: 189–94.
- Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. *Annu Rev Cell Dev Biol* 2011; 27: 107–32.
- Murmu RP, Martin E, Rastetter A, Esteves T, Muriel MP, El Hachimi KH, et al. Cellular distribution and subcellular localization of spatacsin and spastizin, two proteins involved in hereditary spastic paraplegia. *Mol Cell Neurosci* 2011; 47: 191–202.
- Nemeth AH, Kwasniewska AC, Lise S, Parolin Schnekenberg R, Becker EB, Bera KD, et al. Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. *Brain* 2013; 136(Pt 10): 3106–18.
- Nishioka K, Oyama G, Yoshino H, Li Y, Matsushima T, Takeuchi C, et al. High frequency of beta-propeller protein-associated neurodegeneration (BPAN) among patients with intellectual disability and young-onset parkinsonism. *Neurobiol Aging* 2015; 36: 2004.e9–15.
- Nishiyama J, Miura E, Mizushima N, Watanabe M, Yuzaki M. Aberrant membranes and double-membrane structures accumulate in the axons of Atg5-null Purkinje cells before neuronal death. *Autophagy* 2007; 3: 591–6.
- Nixon RA. The role of autophagy in neurodegenerative disease. *Nat Med* 2013; 19: 983–97.
- Noreau A, Dion PA, Rouleau GA. Molecular aspects of hereditary spastic paraplegia. *Exp Cell Res* 2014; 325: 18–26.
- Ohba C, Nabatame S, Iijima Y, Nishiyama K, Tsurusaki Y, Nakashima M, et al. *De novo* WDR45 mutation in a patient showing clinically Rett syndrome with childhood iron deposition in brain. *J Hum Genet* 2014; 59: 292–5.
- Okamoto K. Organellophagy: Eliminating cellular building blocks via selective autophagy. *J Cell Biol* 2014; 205: 435–45.
- Oku M, Sakai Y. Peroxisomes as dynamic organelles: autophagic degradation. *FEBS J* 2010; 277: 3289–94.
- Orsi A, Razi M, Dooley HC, Robinson D, Weston AE, Collinson LM, et al. Dynamic and transient interactions of Atg9 with autophagosomes, but not membrane integration, are required for autophagy. *Mol Biol Cell* 2012; 23: 1860–73.
- Oz-Levi D, Ben-Zeev B, Ruzzo EK, Hitomi Y, Gelman A, Pelak K, et al. Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. *Am J Hum Genet* 2012; 91: 1065–72.
- Ozawa T, Koide R, Nakata Y, Saito H, Matsumoto N, Takahashi K, et al. A novel WDR45 mutation in a patient with static encephalopathy of childhood with neurodegeneration in adulthood (SENDA). *Am J Med Genet A* 2014; 164a: 2388–90.
- Ozkale M, Erol I, Gumus A, Ozkale Y, Alehan F. Vici syndrome associated with sensorineural hearing loss and laryngomalacia. *Pediatr Neurol* 2012; 47: 375–8.
- Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, et al. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. *Hum Mol Genet* 2011; 20: 3852–66.
- Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. *Brain* 2008a; 131(Pt 8): 1969–78.
- Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. *Neurobiol Dis* 2008b; 32: 16–25.
- Papinski D, Schuschnig M, Reiter W, Wilhelm L, Barnes CA, Maiolica A, et al. Early steps in autophagy depend on direct phosphorylation of Atg9 by the Atg1 kinase. *Mol Cell* 2014; 53: 471–83.
- Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. *Cell* 2008; 134: 877–86.
- Pastore N, Blomenkamp K, Annunziata F, Piccolo P, Mithbaokar P, Maria Sepe R, et al. Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-anti-trypsin deficiency. *EMBO Mol Med* 2013; 5: 397–412.
- Paudel R, Li A, Wiethoff S, Bandopadhyay R, Bhatia K, de Silva R, et al. Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy. *Acta Neuropathol Commun* 2015; 3: 39.
- Pensato V, Castellotti B, Gellera C, Pareyson D, Ciano C, Nanetti L, et al. Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. *Brain* 2014; 137(Pt 7): 1907–20.
- Platt FM. Sphingolipid lysosomal storage disorders. *Nature* 2014; 510: 68–75.
- Proikas-Cezanne T, Waddell S, Gaugel A, Frickey T, Lupas A, Nordheim A. WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. *Oncogene* 2004; 23: 9314–25.
- Pyle A, Smertenko T, Bargiela D, Griffin H, Duff J, Appleton M, et al. Exome sequencing in undiagnosed inherited and sporadic ataxias. *Brain* 2015; 138(Pt 2): 276–83.
- Rathore GS, Schaaf CP, Stocco AJ. Novel mutation of the WDR45 gene causing beta-propeller protein-associated neurodegeneration. *Mov Disord* 2014; 29: 574–5.
- Ravenscroft G, Laing NG, Bonnemann CG. Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus. *Brain* 2015; 138(Pt 2): 246–68.
- Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy



- in physiology and pathophysiology. *Physiol Rev* 2010; 90: 1383–435.
- Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 2004; 36: 585–95.
- Renvoise B, Chang J, Singh R, Yonekawa S, FitzGibbon EJ, Mankodi A, et al. Lysosomal abnormalities in hereditary spastic paraplegia types SPG15 and SPG11. *Ann Clin Transl Neurol* 2014; 1: 379–89.
- Rocznik-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. *Sci Signal* 2012; 5: ra42.
- Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, Solano RM, Gomez A, Perucho J, et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. *Neurobiol Dis* 2010; 39: 423–38.
- Rogers RC, Aufmuth B, Monesson S. Vici syndrome: a rare autosomal recessive syndrome with brain anomalies, cardiomyopathy, and severe intellectual disability. *Case Rep Genet* 2011; 2011: 421582.
- Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. *Hum Mol Genet* 2010; 19: 2144–53.
- Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat Rev Drug Discov* 2012; 11: 709–30.
- Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. *Nat Cell Biol* 2013; 15: 741–50.
- Said E, Soler D, Sewry C. Vici syndrome—a rapidly progressive neurodegenerative disorder with hypopigmentation, immunodeficiency and myopathic changes on muscle biopsy. *Am J Med Genet A* 2012; 158A: 440–4.
- Saitsu H, Nishimura T, Muramatsu K, Kodera H, Kumada S, Sugai K, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. *Nat Genet* 2013; 45: 445–9, 449e1.
- Salinas S, Proukakis C, Crosby A, Warner TT. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. *Lancet Neurol* 2008; 7: 1127–38.
- Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating lysosomal biogenesis and function. *Science* 2009; 325: 473–7.
- Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. *J Biol Chem* 2007a; 282: 5641–52.
- Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. *J Cell Biol* 2005; 170: 1101–11.
- Sarkar S, Maetzel D, Korolchuk VI, Jaenisch R. Restarting stalled autophagy a potential therapeutic approach for the lipid storage disorder, Niemann-Pick type C1 disease. *Autophagy* 2014; 10: 1137–40.
- Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. *Nat Chem Biol* 2007b; 3: 331–8.
- Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. *Brain* 2012; 135(Pt 7): 2169–77.
- Schule R, Schlipf N, Synofzik M, Klebe S, Klimpe S, Hehr U, et al. Frequency and phenotype of SPG11 and SPG15 in complicated hereditary spastic paraplegia. *J Neurol Neurosurg Psychiatry* 2009; 80: 1402–4.
- Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. *Science* 2011; 332: 1429–33.
- Shacka JJ, Klocke BJ, Shibata M, Uchiyama Y, Datta G, Schmidt RE, et al. Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. *Mol Pharmacol* 2006; 69: 1125–36.
- Shibasaki Y, Tanaka H, Iwabuchi K, Kawasaki S, Kondo H, Uekawa K, et al. Linkage of autosomal recessive hereditary spastic paraplegia with mental impairment and thin corpus callosum to chromosome 15A13-15. *Ann Neurol* 2000; 48: 108–12.
- Shimada K, Motoi Y, Ishiguro K, Kambe T, Matsumoto SE, Itaya M, et al. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. *Neurobiol Dis* 2012; 46: 101–8.
- Shu XH, Wang LL, Li H, Song X, Shi S, Gu JY, et al. Diffusion efficiency and bioavailability of resveratrol administered to rat brain by different routes: therapeutic implications. *Neurotherapeutics* 2015; 12: 491–501.
- Slabicki M, Theis M, Krastev DB, Samsonov S, Mundwiler E, Junqueira M, et al. A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. *PLoS Biol* 2010; 8: e1000408.
- Sousa SB, Ramos F, Garcia P, Pais RP, Paiva C, Beales PL, et al. Intellectual disability, coarse face, relative macrocephaly, and cerebellar hypotrophy in two sisters. *Am J Med Genet A* 2014; 164A: 10–4.
- Spampanato C, Feeney E, Li L, Cardone M, Lim JA, Annunziata F, et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. *EMBO Mol Med* 2013; 5: 691–706.
- Stadel D, Millarte V, Tillmann KD, Huber J, Tamin-Yecheskel BC, Akutsu M, et al. TECPR2 cooperates with LC3C to regulate COPII-dependent ER export. *Mol Cell* 2015; 60: 89–104.
- Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, et al. Latrepirdine stimulates autophagy and reduces accumulation of alpha-synuclein in cells and in mouse brain. *Mol Psychiatry* 2013a; 18: 882–8.
- Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. *Mol Psychiatry* 2013b; 18: 889–97.
- Stevanin G, Azzedine H, Denora P, Boukhris A, Tazir M, Lossos A, et al. Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. *Brain* 2008; 131(Pt 3): 772–84.
- Stevanin G, Santorelli FM, Azzedine H, Coutinho P, Chomilier J, Denora PS, et al. Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. *Nat Genet* 2007; 39: 366–72.
- Stirmimann CU, Petsalaki E, Russell RB, Muller CW. WD40 proteins propel cellular networks. *Trends Biochem Sci* 2010; 35: 565–74.
- Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. *Nat Cell Biol* 2014; 16: 495–501.
- Suzuki K. Selective autophagy in budding yeast. *Cell Death Differ* 2013; 20: 43–8.
- Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. *Neuron* 2014; 83: 1131–43.
- Tasdemir S, Sahin I, Cayir A, Yuce I, Ceylaner S, Tatar A. Vici syndrome in siblings born to consanguineous parents. *Am J Med Genet A* 2015.
- Thomas AC, Williams H, Seto-Salvia N, Bacchelli C, Jenkins D, O'Sullivan M, et al. Mutations in SNX14 cause a distinctive autosomal-recessive cerebellar ataxia and intellectual disability syndrome. *Am J Hum Genet* 2014; 95: 611–21.
- Tian Y, Bustos V, Flajolet M, Greengard P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. *FASEB J* 2011; 25: 1934–42.
- Tian Y, Li Z, Hu W, Ren H, Tian E, Zhao Y, et al. C. elegans screen identifies autophagy genes specific to multicellular organisms. *Cell* 2010; 141: 1042–55.



- Tsai PT, Hull C, Chu Y, Greene-Colozzi E, Sadowski AR, Leech JM, et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. *Nature* 2012; 488: 647–51.
- Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, et al. PGC-1 $\alpha$  rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. *Sci Transl Med* 2012; 4: 142ra97.
- Van Goethem G, Livingston JH, Warren D, Ojageer AJ, Rice GI, Crow YJ. Basal ganglia calcification in a patient with beta-propeller protein-associated neurodegeneration. *Pediatr Neurol* 2014; 51: 843–5.
- Vantaggiato C, Clementi E, Bassi MT. ZFYVE26/SPASTIZIN: a close link between complicated hereditary spastic paraparesis and autophagy. *Autophagy* 2014; 10: 374–5.
- Vantaggiato C, Crimella C, Airoldi G, Polishchuk R, Bonato S, Brighina E, et al. Defective autophagy in spastizin mutated patients with hereditary spastic paraparesis type 15. *Brain* 2013; 136(Pt 10): 3119–39.
- Varga RE, Khundadze M, Damme M, Nietzsche S, Hoffmann B, Stauber T, et al. In Vivo evidence for lysosome depletion and impaired autophagic clearance in hereditary spastic paraplegia type SPG11. *PLoS Genet* 2015; 11: e1005454.
- Verhoeven WM, Egger JI, Koolen DA, Yntema H, Olgiati S, Breedveld GJ, et al. Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: novel mutations and neuropsychiatric phenotype in three adult patients. *Parkinsonism Relat Disord* 2014; 20: 332–6.
- Vicinanza M, Korolchuk VI, Ashkenazi A, Puri C, Menzies FM, Clarke JH, et al. PI(5)P regulates autophagosome biogenesis. *Mol Cell* 2015; 57: 219–34.
- Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. *J Biol Chem* 2010; 285: 9100–13.
- Viscomi MT, D'Amelio M, Cavallucci V, Latini L, Bisicchia E, Nazio F, et al. Stimulation of autophagy by rapamycin protects neurons from remote degeneration after acute focal brain damage. *Autophagy* 2012; 8: 222–35.
- Vite CH, Bagel JH, Swain GP, Prociuk M, Sikora TU, Stein VM, et al. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. *Sci Transl Med.* 2015;7:276ra26.
- Vodicka P, Lim J, Williams DT, Kegel KB, Chase K, Park H, et al. Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice. *J Huntingtons Dis* 2014; 3: 159–74.
- Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. *Proc Natl Acad Sci USA* 2012a; 109: 15024–9.
- Wang RC, Wei Y, An Z, Zou Z, Xiao G, Bhagat G, et al. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. *Science* 2012b; 338: 956–9.
- Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. *J Biol Chem* 2003; 278: 25009–13.
- Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. *Nat Chem Biol* 2008; 4: 295–305.
- Wong PM, Puente C, Ganley IG, Jiang X. The ULK1 complex: sensing nutrient signals for autophagy activation. *Autophagy* 2013; 9: 124–37.
- Wurzer B, Zaffagnini G, Fracchiolla D, Turco E, Abert C, Romanov J, et al. Oligomerization of p62 allows for selection of ubiquitinated cargo and isolation membrane during selective autophagy. *Elife* 2015; 4.
- Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, et al. Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. *Neuroscience* 2011; 199: 292–302.
- Yamamoto A, Simonsen A. The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. *Neurobiol Dis* 2011; 43: 17–28.
- Yamamoto H, Kakuta S, Watanabe TM, Kitamura A, Sekito T, Kondo-Kakuta C, et al. Atg9 vesicles are an important membrane source during early steps of autophagosome formation. *J Cell Biol* 2012; 198: 219–33.
- Yasin SA, Ali AM, Tata M, Picker SR, Anderson GW, Latimer-Bowman E, et al. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis. *Acta Neuropathol* 2013; 126: 207–18.
- Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. *Nature* 2010; 465: 942–6.
- Zhang X, Chen S, Song L, Tang Y, Shen Y, Jia L, et al. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. *Autophagy* 2014; 10: 588–602.
- Zhao H, Zhao YG, Wang X, Xu L, Miao L, Feng D, et al. Mice deficient in Epg5 exhibit selective neuronal vulnerability to degeneration. *J Cell Biol* 2013a; 200: 731–41.
- Zhao YG, Sun L, Miao G, Ji C, Zhao H, Sun H, et al. The autophagy gene Wdr45/Wipi4 regulates learning and memory function and axonal homeostasis. *Autophagy* 2015; 11: 881–90.
- Zhao YG, Zhao H, Sun H, Zhang H. Role of Epg5 in selective neurodegeneration and Vici syndrome. *Autophagy* 2013b; 9: 1258–62.
- Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, et al. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. *Nat Cell Biol* 2009; 11: 468–76.